Pentapeptide modified resin
    1.
    发明授权
    Pentapeptide modified resin 失效
    五肽改性树脂

    公开(公告)号:US4258152A

    公开(公告)日:1981-03-24

    申请号:US47909

    申请日:1979-06-12

    IPC分类号: A61K38/00 C07K5/062 C08F8/30

    摘要: There are disclosed polypeptide compositions having the following amino acid sequence as the active site:ARG-LYS-ASP-VAL-TYRThese polypeptides have the capability of inducing the differentiation of T-lymphocytes but not of complement receptor (CR.sup.+) B-lymphocytes and thus are useful in a number of therapeutic areas. Also provided are derivatives of the pentapeptide, novel intermediate polypeptides, methods of manufacture of the peptides, therapeutic compositions, and methods for use of the compositions.

    摘要翻译: 公开了具有以下氨基酸序列作为活性位点的多肽组合物:ARG-LYS-ASP-VAL-TYR这些多肽具有诱导T淋巴细胞分化而不是补体受体(CR +)B淋巴细胞分化的能力, 因此在许多治疗领域中是有用的。 还提供了五肽的衍生物,新的中间体多肽,肽的制备方法,治疗组合物和使用该组合物的方法。

    Polypeptides and methods
    3.
    发明授权
    Polypeptides and methods 失效
    多肽和方法

    公开(公告)号:US4190647A

    公开(公告)日:1980-02-26

    申请号:US6894

    申请日:1979-01-26

    CPC分类号: C07K7/06 C07K14/575 A61K38/00

    摘要: There are disclosed new polypeptide compositions having the following amino acid sequence as the active site:TYR-ASN-ILE-GLN-LYSThis polypeptide has the capability of inducing the differentiation of both T-precursor cells as measured by the acquisition of the thymic differentiation antigens TL and THY-1 (.theta.), as well as B-precursor cells as measured by the acquisition of receptors for complement, a distinctive marker of B cells. The peptide is thus useful in thymic function and immunity areas such as in treatment for a congenital absence of thymus. The peptide is active in very low concentrations. Also provided are derivatives of the pentapeptide, novel intermediate polypeptides, methods of manufacture of the peptides, therapeutic compositions, and methods for use of the compositions.

    摘要翻译: 公开了具有以下氨基酸序列作为活性位点的新的多肽组合物:TYR-ASN-ILE-GLN-LYS该多肽具有诱导两种T前体细胞分化的能力,如通过获得胸腺分化所测量的 抗原TL和THY-1(θ),以及通过获得补体受体(B细胞的独特标记物)测量的B前体细胞。 因此,该肽可用于胸腺功能和免疫领域,例如先天性缺乏胸腺的治疗。 该肽在非常低的浓度下是有活性的。 还提供了五肽的衍生物,新的中间体多肽,肽的制备方法,治疗组合物和使用该组合物的方法。

    Pentapeptide modified resin
    4.
    发明授权
    Pentapeptide modified resin 失效
    五肽改性树脂

    公开(公告)号:US4258151A

    公开(公告)日:1981-03-24

    申请号:US47907

    申请日:1979-06-12

    摘要: There are disclosed new polypeptide compositions having the following amino acid sequence as the active site:TYR-ASN-ILE-GLN-LYSThis polypeptide has the capability of inducing the differentiation of both T-precursor cells as measured by the acquisition of the thymic differentiation antigens TL and THY-1 (.theta.), as well as B-precursor cells as measured by the acquisition of receptors for complement, a distinctive marker of B cells. The peptide is thus useful in thymic function and immunity areas such as in treatment for a congenital absence of thymus. The peptide is active in very low concentrations. Also provided are derivatives of the pentapeptide, novel intermediate polypeptides, methods of manufacture of the peptides, therapeutic compositions, and methods for use of the compositions.

    摘要翻译: 公开了具有以下氨基酸序列作为活性位点的新的多肽组合物:TYR-ASN-ILE-GLN-LYS该多肽具有诱导两种T前体细胞分化的能力,如通过获得胸腺分化所测量的 抗原TL和THY-1(θ),以及通过获得补体受体(B细胞的独特标记物)测量的B前体细胞。 因此,该肽可用于胸腺功能和免疫领域,例如先天性缺乏胸腺的治疗。 该肽在非常低的浓度下是有活性的。 还提供了五肽的衍生物,新的中间体多肽,肽的制备方法,治疗组合物和使用该组合物的方法。

    Polypeptide compositions and methods
    5.
    发明授权
    Polypeptide compositions and methods 失效
    多肽组合物和方法

    公开(公告)号:US4190646A

    公开(公告)日:1980-02-26

    申请号:US6893

    申请日:1979-01-26

    摘要: There are disclosed polypeptide compositions having the following amino acid sequence as the active site:ARG-LYS-ASP-VAL-TYRThese polypeptides have the capability of inducing the differentiation of T-lymphocytes but not of complement receptor (CR.sup.+) B-lymphocytes and thus are useful in a number of therapeutic areas. Also provided are derivatives of the pentapeptide, novel intermediate polypeptides, methods of manufacture of the peptides, therapeutic compositions, and methods for use of the compositions.

    摘要翻译: 公开了具有以下氨基酸序列作为活性位点的多肽组合物:ARG-LYS-ASP-VAL-TYR这些多肽具有诱导T淋巴细胞分化而不是补体受体(CR +)B淋巴细胞分化的能力, 因此在许多治疗领域中是有用的。 还提供了五肽的衍生物,新的中间体多肽,肽的制备方法,治疗组合物和使用该组合物的方法。